Article
LRRK2 G2019S mutations are associated with an increased cancer risk in Parkinson disease.
Movement disorders : official journal of the Movement Disorder Society - 15 Nov 2010
Saunders-Pullman Rachel, Barrett Matthew J, Stanley Kaili M, Luciano Marta San, Shanker Vicki, Severt Lawrence, Hunt Ann, Raymond Deborah, Ozelius Laurie J, Bressman Susan B
Abstract excerpt
Leucine rich repeat kinase (LRRK2) G2019S mutations are presumed to cause PD through a toxic gain of function of the protein kinase. Small molecule kinase inhibitors have been developed for the treatment of certain cancers, and some antioncogenic agents such as sunitinib, may nonspecifically inhibit LRRK2. Few studies, however, have assessed cancer risk in LRRK2 mutation carriers. To explore this risk, we...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.